Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Gut

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 2 · 28.6%High 2 · 28.6%

Once daily dosing vs conventional dosing

Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to induce global or clinical remission compared with conventional dosing (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.99 [0.93, 1.06]
5 studies · 1761 participants
High

Once daily dosing vs conventional dosing

Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to induce global or clinical improvement compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.74 [0.49, 1.1]
3 studies · 564 participants
Moderate

Once daily dosing vs conventional dosing

Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to induce endoscopic remission compared with conventional dosing (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.02 [0.98, 1.07]
1 study · 817 participants
High

Once daily dosing vs conventional dosing

Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to adhere to medication regimen compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.36 [0.64, 2.86]
2 studies · 358 participants
Low

Once daily dosing vs conventional dosing

Adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in adverse events compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.02 [0.89, 1.18]
4 studies · 1586 participants
Moderate

Once daily dosing vs conventional dosing

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.34 [0.68, 2.66]
4 studies · 1586 participants
Low

Once daily dosing vs conventional dosing

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in withdrawal due to adverse events compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.89 [0.54, 1.49]
5 studies · 1757 participants
Low